The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2415-2425

  Zhao, Liqun ^a   Yue, Ping ^a   Lonial, Sagar ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; MLN 4924; NEDD8 PROTEIN; PROTEASOME; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CYCLOPENTANES; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; PROTEOLYSIS; PYRIMIDINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; UBIQUITINATION; UP-REGULATION;

EID: 83355174037     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0401     Document Type: Article

References (37)

1. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9. (Pubitemid 38987058)
2. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 2005;16:55-76. (Pubitemid 40279117)
3. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
4. Wajant H. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol Interv 2003;3:124-7.
5. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010;42:210-3.
6. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002;277:22320-9. (Pubitemid 34967199)
7. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS, et al. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 2005;280: 27345-55. (Pubitemid 41040776)
8. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. Cellular FLICEinhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res 2006; 66:11115-9. (Pubitemid 46009936)
9. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 2010;12: 346-56.
10. Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, et al. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther 2008;7:2212-23.
11. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalphainduced cell death by inducing c-FLIP(L) turnover. Cell 2006;124: 601-13. (Pubitemid 43199444)
12. Rabut G, Peter M. Function and regulation of protein neddylation. Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008;9:969-76.
13. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20. (Pubitemid 40064895)
14. Kawakami T, Chiba T, Suzuki T, Iwai K, Yamanaka K, Minato N, et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 2001;20: 4003-12. (Pubitemid 32751817)
15. Leck YC, Choo YY, Tan CY, Smith PG, Hagen T. Biochemical and cellular effects of inhibiting Nedd8 conjugation. Biochem Biophys Res Commun 2010;398:588-93.
16. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin- RING ligases for the treatment of cancer. Clin Cancer Res 2009;15: 3912-6.
17. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
18. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37:102-11.
19. Chairatvit K, Ngamkitidechakul C. Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Mol Cell Biochem 2007;306:163-9. (Pubitemid 350001828)
20. Jin F, Liu X, Zhou Z, Yue P, Lotan R, Khuri FR, et al. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 2005;65:6354-63. (Pubitemid 40994422)
21. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000;6:1563-73. (Pubitemid 30226247)
22. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997;57:4931-9. (Pubitemid 27469005)
23. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999;18: 2357-65. (Pubitemid 29192713)
24. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004;96:1769-80. (Pubitemid 39654571)
25. Chen S, Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. CHOP-dependent DR5 induction and ubiquitin/proteasome-mediated c-FLIPdownregulation contribute to enhancement of TRAIL-induced apoptosis by dimethyl-celecoxib in human non-small cell lung cancer cells. Mol Pharmacol 2007;72:1269-79.
26. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009;4:34-41.
27. Falschlehner C, GantenTM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009;647:195-206.
28. Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2007;7:163-73.
29. Sun SY. Chemopreventive agent-induced modulation of death receptors. Apoptosis 2005;10:1203-10.
30. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37. (Pubitemid 40315182)
31. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, et al. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid- induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 2008;7:3556-65.
32. Kaunisto A, Kochin V, Asaoka T, Mikhailov A, Poukkula M, Meinander A, et al. PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ 2009;16:1215-26.
33. Shi B, Tran T, Sobkoviak R, Pope RM. Activation-induced degradation of FLIP(L) is mediated via the phosphatidylinositol 3-kinase/ Akt signaling pathway in macrophages. J Biol Chem 2009;284: 14513-23.
34. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299-305. (Pubitemid 32702435)
35. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- {kappa}B-dependent lymphoma. Blood 2010;116:1515-23.
36. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800.
37. Shishodia S, Aggarwal BB. Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol 2004;68:1071-80. (Pubitemid 39094272)